Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.
2018 ◽
Vol 36
(15_suppl)
◽
pp. 1052-1052
◽